We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Fig. 1 · Structure
Cat. No.
A11590
CAS No.
259793-96-9
Formula
C5H4FN3O2
Mol. Weight
157.1

Documents & Downloads

Favipiravir (T-705)

viral RNA polymerase inhibitor

T-705, a substituted pyrazine compound, has been found to exhibit potent anti-influenza virus activity in vitro and in vivo.

In Stock

Publications for Favipiravir

13 publications citing this product

  1. Thomas R Lane, .et al. , ACS Infect Dis, 2026, May 8;12(5):1776-1789 PMID: 42052926
  2. Dylan M Johnson, .et al. , Viruses, 2024, Jul 9;16(7):1101 PMID: 39066263
  3. Steven B Tillis, .et al. , Microorganisms, 2023, May 24;11(6):1371 PMID: 37374873
  4. Hyeon-Min Cha, .et al. , ACS Infect Dis, 2023, Apr 14;9(4):1033-1045 PMID: 36912867
  5. Satoko Yamaoka, .et al. , Antiviral Res, 2022, Apr;200:105291 PMID: 35296419
  6. Crystal A Mendoza, .et al. , Antiviral Res, 2021, Jan;185:104993 PMID: 33296695
  7. Liva Checkmahomed, .et al. , Viruses, 2020, Oct; 12(10): 1139 PMID: 33049959
  8. JE Comer, .et al. , Viruses, 2019, Feb 3;11(2). pii: E137 PMID: 30717492
  9. Ma J, .et al. , Antiviral Res, 2018, Feb;150:112-122 PMID: 29253498
  10. Ji-Ae Kim, .et al. , Viruses, 2018, Feb; 10(2): 72 PMID: 29425176
Notify me when the price drops

For laboratory research use only. We do not sell to patients.

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
RNA-dependent RNA polymerase

Cellular Effect

Cell Line Activity Value Description Reference
MDCK CC50 > 100 μM Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay [PMID: 36764470]
MDCK CC50 > 100 μM Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis [PMID: 23419738]
MDCK CC50 > 250 μM Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay [PMID: 29906392]
MDCK CC50 > 250 μM Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay [PMID: 29906392]
MDCK CC50 > 400 μM Cytotoxicity against MDCK cells after 10 mins by CellTiter-Glo assay [PMID: 27120583]
MDCK EC50 0.19 μM Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi [PMID: 20350949]
MDCK EC50 0.38 μM Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain [PMID: 20350949]
MDCK EC50 0.45 μM Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis [PMID: 20350949]
MDCK EC50 0.57 μM Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana [PMID: 20350949]
MDCK EC50 0.83 μM Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros [PMID: 20350949]
MDCK EC50 0.83 μM Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet [PMID: 20350949]
MDCK EC50 0.83 μM Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros [PMID: 20350949]
MDCK EC50 0.89 μM Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco [PMID: 20350949]
MDCK EC50 0.89 μM Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days [PMID: 20350949]
MDCK EC50 0.96 μM Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet [PMID: 20350949]
MDCK EC50 1.21 μM Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af [PMID: 20350949]
MDCK EC50 1.21 μM Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain [PMID: 20350949]

17 records · Scroll to view more

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 259793-96-9
Applications viral RNA polymerase inhibitor
Formula C5H4FN3O2
Molecular Weight 157.1
Synonyms T705
SMILES
C1=C(N=C(C(=O)N1)C(=O)N)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 29 mg/mL (184.59 mM)
Water Warmed: 5 mg/mL (31.82 mM)
Ethanol Warmed: 21 mg/mL (133.67 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Publications

13 publications citing this product

  1. Thomas R Lane, .et al. , ACS Infect Dis, 2026, May 8;12(5):1776-1789 PMID: 42052926
  2. Dylan M Johnson, .et al. , Viruses, 2024, Jul 9;16(7):1101 PMID: 39066263
  3. Steven B Tillis, .et al. , Microorganisms, 2023, May 24;11(6):1371 PMID: 37374873
  4. Hyeon-Min Cha, .et al. , ACS Infect Dis, 2023, Apr 14;9(4):1033-1045 PMID: 36912867
  5. Satoko Yamaoka, .et al. , Antiviral Res, 2022, Apr;200:105291 PMID: 35296419
  6. Crystal A Mendoza, .et al. , Antiviral Res, 2021, Jan;185:104993 PMID: 33296695
  7. Liva Checkmahomed, .et al. , Viruses, 2020, Oct; 12(10): 1139 PMID: 33049959
  8. JE Comer, .et al. , Viruses, 2019, Feb 3;11(2). pii: E137 PMID: 30717492
  9. Ma J, .et al. , Antiviral Res, 2018, Feb;150:112-122 PMID: 29253498
  10. Ji-Ae Kim, .et al. , Viruses, 2018, Feb; 10(2): 72 PMID: 29425176
  11. Haejin Chun, .et al. , Polym Chem, 2018, 9: 2116-2123
  12. Baz M, .et al. , Viruses, 2018, Nov 3;10(11) PMID: 30400276
  13. Sehee Park, .et al. , PLoS One., 2014, 9(7): e101325 PMID: 24992479

Showing 10 of 13 publications

Added to your cart

View Cart Checkout
Loading...